The Broad Institute of MIT and Harvard on Monday withstood a second closely watched challenge to its CRISPR-Cas9 patents, as the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback